Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down
- Author
- LANKESTER, Katharine J1 ; MAXWELL, Ross J1 ; PEDLEY, R. Barbara2 ; DEARLING, Jason L2 ; QURESHI, Uzma A2 ; EL-EMIR, Ethaar2 ; HILL, Sally A1 ; TOZER, Gillian M1
[1] Gray Cancer Institute, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middx, HA6 2JR, United Kingdom
[2] Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School Hampstead Campus, UCL, London, NW3 2PF, United Kingdom - Source
International journal of oncology. 2007, Vol 30, Num 2, pp 453-460, 8 p ; ref : 50 ref
- ISSN
- 1019-6439
- Scientific domain
- Medical oncology
- Publisher
- Editorial Academy of the International Journal of Oncology, Athens
- Publication country
- Greece
- Document type
- Article
- Language
- English
- Author keyword
- 131I-A5B7 CA-4-P MRI radioimmunotherapy vascular disrupting agents
- Keyword (fr)
- Anticorps Cancérologie Dose Imagerie RMN Immunoradiothérapie Iodure(131I) de sodium Radioisotope Radiothérapie Traitement Tumeur Vaisseau sanguin Appareil circulatoire Imagerie médicale
- Keyword (en)
- Antibody Cancerology Dose Nuclear magnetic resonance imaging Immunoradiotherapy Sodium iodide(131I) Radioisotope Radiotherapy Treatment Tumor Blood vessel Circulatory system Medical imagery
- Keyword (es)
- Anticuerpo Cancerología Dosis Imaginería RMN Inmunoradioterapia Ioduro sódico(131I) Radionúclido Radioterapia Tratamiento Tumor Vaso sanguíneo Aparato circulatorio Imaginería médica
- Classification
- Discipline
- Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18449206
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:9:\"\u0000*\u0000jtitle\";s:33:\"International journal of oncology\";s:9:\"\u0000*\u0000stitle\";s:13:\"Int. j. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"460\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1019-6439\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LANKESTER\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Katharine J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:15:\"MAXWELL, Ross J\";i:1;s:18:\"PEDLEY, R. Barbara\";i:2;s:17:\"DEARLING, Jason L\";i:3;s:15:\"QURESHI, Uzma A\";i:4;s:15:\"EL-EMIR, Ethaar\";i:5;s:13:\"HILL, Sally A\";i:6;s:16:\"TOZER, Gillian M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:58:\"Editorial Academy of the International Journal of Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:9:\"\u0000*\u0000jtitle\";s:33:\"International journal of oncology\";s:9:\"\u0000*\u0000stitle\";s:13:\"Int. j. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"460\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1019-6439\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LANKESTER\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Katharine J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:15:\"MAXWELL, Ross J\";i:1;s:18:\"PEDLEY, R. Barbara\";i:2;s:17:\"DEARLING, Jason L\";i:3;s:15:\"QURESHI, Uzma A\";i:4;s:15:\"EL-EMIR, Ethaar\";i:5;s:13:\"HILL, Sally A\";i:6;s:16:\"TOZER, Gillian M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:58:\"Editorial Academy of the International Journal of Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:9:\"\u0000*\u0000jtitle\";s:33:\"International journal of oncology\";s:9:\"\u0000*\u0000stitle\";s:13:\"Int. j. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"460\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1019-6439\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LANKESTER\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Katharine J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:15:\"MAXWELL, Ross J\";i:1;s:18:\"PEDLEY, R. Barbara\";i:2;s:17:\"DEARLING, Jason L\";i:3;s:15:\"QURESHI, Uzma A\";i:4;s:15:\"EL-EMIR, Ethaar\";i:5;s:13:\"HILL, Sally A\";i:6;s:16:\"TOZER, Gillian M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:58:\"Editorial Academy of the International Journal of Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:9:\"\u0000*\u0000jtitle\";s:33:\"International journal of oncology\";s:9:\"\u0000*\u0000stitle\";s:13:\"Int. j. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"460\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1019-6439\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"LANKESTER\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Katharine J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:15:\"MAXWELL, Ross J\";i:1;s:18:\"PEDLEY, R. Barbara\";i:2;s:17:\"DEARLING, Jason L\";i:3;s:15:\"QURESHI, Uzma A\";i:4;s:15:\"EL-EMIR, Ethaar\";i:5;s:13:\"HILL, Sally A\";i:6;s:16:\"TOZER, Gillian M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:164:\"Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:58:\"Editorial Academy of the International Journal of Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
